R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs ACADIA Pharmaceuticals Inc.

Biopharma R&D: ACADIA vs. Intra-Cellular Therapies

__timestampACADIA Pharmaceuticals Inc.Intra-Cellular Therapies, Inc.
Wednesday, January 1, 20146060200021226345
Thursday, January 1, 20157386900087718074
Friday, January 1, 20169928400093831530
Sunday, January 1, 201714918900079419009
Monday, January 1, 2018187163000132166913
Tuesday, January 1, 201924038500089124838
Wednesday, January 1, 202031913000065782137
Friday, January 1, 202123941500088845513
Saturday, January 1, 2022361575000134715000
Sunday, January 1, 2023351619000180142000
Loading chart...

Unveiling the hidden dimensions of data

R&D Spending Trends in Biopharmaceuticals: A Decade of Innovation

In the competitive world of biopharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and Intra-Cellular Therapies, Inc. have been at the forefront of this race. From 2014 to 2023, ACADIA Pharmaceuticals has consistently outpaced its competitor, with R&D expenses peaking at a staggering 360% increase by 2022 compared to 2014. Intra-Cellular Therapies, while trailing, has shown a remarkable 750% growth in R&D spending over the same period, highlighting its aggressive push towards innovation. The year 2023 marked a significant milestone for Intra-Cellular Therapies, as it reached its highest R&D expenditure, closing the gap with ACADIA. This trend underscores the dynamic nature of the biopharmaceutical industry, where strategic investments in R&D can lead to groundbreaking advancements and competitive advantages.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025